Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Aug 17, 2017 12:59pm
48 Views
Post# 26592460

RE:RE:RE:RE:Game with extremely high risk

RE:RE:RE:RE:Game with extremely high riskIf I was smarter and less of a gambler, I would only get in come late Dec 2017.
That is, just before they announce the results of the study.
Yes the share price will most likely be up by then, maybe 0.15, maybe 0.25...
However you dramatically reduce the risk of being in while a catastrophic failure happens in the study and they go bankrupt. We are very exposed as it stands.
That being said we have the highest upside right now as the longer we wait (closer to study results) the higher the price will be.
I'm a bit of a gambling man and I believe their research has enough basis to prove a very low likelyhood of catastrophic failure and that's why I'm in now.
However If i was not already invested I would probably wait till end of year.
For that reason I believe the share price will linger between 0.08-0.15 till Nov-Dec.
Because many more people are smarter then I am (more risk averse anyway).
Just my thoughts.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities